Clear Street’s enGene Therapeutics Warrants ENGNW Stock Holding History

Clear Street’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58	Sell	200 -100	-33%	-$104	﹤0.01%	1361
2026 Q1	$759	Hold	300	–	–	﹤0.01%	1050
2025 Q4	$888	Hold	300	–	–	﹤0.01%	875
2025 Q3	$213	Hold	300	–	–	﹤0.01%	797
2025 Q2	$246	Hold	300	–	–	﹤0.01%	634
2025 Q1	$180	Buy	300 +100	+50%	+$82	﹤0.01%	529
2024 Q4	$169	Hold	200	–	–	﹤0.01%	535
2024 Q3	$420	Hold	200	–	–	﹤0.01%	635
2024 Q2	$238	Sell	200 -4,800	-96%	-$15.4K	﹤0.01%	720
2024 Q1	$26K	Sell	5,000 -23,410	-82%	-$71.3K	﹤0.01%	277
2023 Q4	$24.1K	Buy	+28,410	New	+$21.8K	﹤0.01%	252

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Clear Street's ENGNW Position: Q2 2026 in Review

Clear Street reduced its enGene Therapeutics Warrants (ENGNW) stake by 33% in Q2 2026, selling an estimated $104 and leaving 200 shares worth $58. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Clear Street first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $26K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

Clear Street held 200 shares of enGene Therapeutics Warrants worth $58 as of Q2 2026.
Clear Street sold 100 enGene Therapeutics Warrants shares in Q2 2026, an estimated $104.
enGene Therapeutics Warrants made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #1361 holding.
Clear Street first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
Clear Street's enGene Therapeutics Warrants position peaked at $26K in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.